Hikma Pharmaceuticals USA Inc. drugs

55 results

  • Amoxicillin and clavulanate potassium (amoxicillin and clavulanate potassium)

    (Amoxicillin and Clavulanate Potassium)
    Hikma Pharmaceuticals USA Inc.
    Usage: Amoxicillin and Clavulanate Potassium for Oral Suspension treats infections linked to susceptible bacteria in adults and pediatric patients. Indications include lower respiratory tract infections, acute bacterial otitis media, sinusitis, skin and skin structure infections, and urinary tract infections caused by specific beta-lactamase-producing pathogens.

  • Argatroban (argatroban)

    (Argatroban)
    Hikma Pharmaceuticals USA Inc.
    Usage: Argatroban Injection is indicated for the prophylaxis or treatment of thrombosis in adults with heparin-induced thrombocytopenia (HIT) and as an anticoagulant for those undergoing percutaneous coronary intervention (PCI) who are at risk for HIT.

  • Balsalazide disodium (balsalazide disodium)

    (Balsalazide Disodium)
    Hikma Pharmaceuticals USA Inc.
    Usage: Balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients aged 5 years and older. Safety and effectiveness beyond specified durations (8 weeks for pediatric and 12 weeks for adults) have not been established.

  • Bortezomib (bortezomib)

    (bortezomib)
    Hikma Pharmaceuticals USA Inc.
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Bupivacaine hydrochloride (bupivacaine hydrochloride)

    (Bupivacaine Hydrochloride)
    Hikma Pharmaceuticals USA Inc.
    Usage: Bupivacaine Hydrochloride injection is indicated for producing local or regional anesthesia and analgesia in adults during surgical, dental, diagnostic, therapeutic, and obstetrical procedures. Specific concentrations are recommended for different types of blocks; however, not all blocks are suitable due to associated risks.

  • Calcium gluconate (calcium gluconate)

    (calcium gluconate)
    Hikma Pharmaceuticals USA Inc.
    Usage: Calcium Gluconate Injection is indicated for treating acute symptomatic hypocalcemia in pediatric and adult patients. Its long-term safety for use has not been established.

  • Dexamethasone sodium phosphate (dexamethasone sodium phosphate)

    (Dexamethasone Sodium Phosphate)
    Hikma Pharmaceuticals USA Inc.
    Usage: This drug is indicated for intravenous or intramuscular administration in various conditions, including endocrine disorders, rheumatic and collagen diseases, allergic states, ophthalmic and gastrointestinal diseases, respiratory issues, hematologic disorders, neoplastic diseases, edematous states, and nervous system disorders, among others. It also has intra-articular, soft tissue, and intralesional applications for specific inflammatory conditions.

  • Dexmedetomidine hcl (dexmedetomidine hcl)

    (Dexmedetomidine HCl)
    Hikma Pharmaceuticals USA Inc.
    Usage: Dexmedetomidine injection is indicated for sedation in non-intubated patients during surgical and other procedures. Pediatric usage information is available for specific formulations, but this drug product does not include that labeling due to marketing exclusivity.

  • Diltiazem hydrochloride (diltiazem hydrochloride)

    (Diltiazem Hydrochloride)
    Hikma Pharmaceuticals USA Inc.
    Usage: Diltiazem Hydrochloride Injection is indicated for temporary control of rapid ventricular rates in atrial fibrillation or flutter and for converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. Continuous monitoring is essential during administration, with emergency equipment on hand.

  • Dobutamine (dobutamine)

    (Dobutamine)
    Hikma Pharmaceuticals USA Inc.
    Usage: Dobutamine is indicated for short-term intravenous inotropic support in patients experiencing cardiac decompensation due to depressed contractility from heart disease or surgery. Its use is not effective for long-term treatment of congestive heart failure and may increase hospitalization and death risks, especially in NYHA Class IV patients.